Beta Drugs Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.8K Cr
Company aims to grow at a rate between 23%-30% annually across key segments. - Domestic own branded business expected to continue 25%+ growth. - CDMO business expected to grow 5%-10% annually. - Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through. - Dermatology (Derma) segment expected to grow from Rs. Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year. - The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years. - EBITDA margins are expected to be stable around 23% to 25% consolidated. - The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs.
From Beta Drugs Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,328
Market Cap
₹2.8K Cr
P/E Ratio
62.0
How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?
Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Beta Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹94 Cr, net profit ₹9 Cr.
Full financials →📊 Revenue & Sales Performance
- →Company aims to grow at a rate between 23%-30% annually across key segments.
- →Domestic own branded business expected to continue 25%+ growth.
- →CDMO business expected to grow 5%-10% annually.
- →Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through.
- →Dermatology (Derma) segment expected to grow from Rs. 12.3 crores to Rs. 30 crores next year and Rs. 45-50 crores in 3 years.
- →Consolidated revenue guidance for FY26 is around Rs. 450 crores, with a vision to reach Rs. 750 crores by FY28.
- →New product launches (e.g., NDDS, Oral Therapy) and expansions in regulated markets expected to fuel growth.
- →Expected positive EBITDA in Dermatology from FY26 onwards.
- →International markets, including Mexico, Brazil, Philippines, expected to contribute strong growth in coming years.
📈 Profitability & Margins
- →Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year.
- →The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years.
- →EBITDA margins are expected to be stable around 23% to 25% consolidated.
- →The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs. 45-50 crores in sales in 3 years.
- →The Company forecasts consolidated revenue to reach approximately Rs. 750 crore by 2027-28.
- →Net profit rose from Rs. 36.43 crore to Rs. 45.83 crore in FY '25 excluding one-time expenses.
- →The focus remains on sustainable growth, balancing topline and bottom-line improvements with margin stability.
🏗️ Capital Expenditure Plans
- →Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place.
- →Investment of approximately Rs. 11 crores has been made in facility upgrades, mainly in Adley Formulations and Adley Lab.
- →The Company is actively looking for land or a plant for backward integration to manufacture intermediates, reducing dependency on China and ensuring a reliable supply chain for KSMs.
- →R&D team has around 10 people currently, with ongoing investment in scientific and drug delivery system innovations.
- →Potential strategic investments/M&A will be considered if good branded businesses become available, though there is nothing concrete on the table currently.
- →Funds of around Rs. 117 crores raised remain largely parked in FDs, with selective utilization ongoing as opportunities arise.
💰 Fundraising & Capital Structure
- →The company recently raised approximately Rs. 117 crores through a preferential issue involving convertible debentures, which carry a coupon leading to higher interest costs.
- →As of now, the funds from this issuance are largely parked in fixed deposits, with around Rs. 11 crores utilized for facility upgrades.
- →There is no mention of any immediate new fundraising plans through debt or equity.
- →The management is exploring growth opportunities, including possible M&A, but currently, there is nothing concrete on the table.
- →Expansions planned include new corporate building for regulatory and R&D functions, and intermediate manufacturing capacity.
- →The company seems well capitalized with a healthy cash position, focusing on utilizing existing raised funds for growth and expansion rather than raising new funds immediately.
📋 Order Book & Pipeline
- →The document does not explicitly mention the current or expected order book or pending orders in numeric terms.
- →Rahul Batra mentions robust business operations with multiple strategic growth plans, indicating strong future demand.
- →CDMO segment has about 30 clients, with 3 new clients added this year, suggesting ongoing and future order inflows.
- →The company is actively preparing dossiers for regulatory approvals in multiple export markets (Mexico, Brazil, Thailand, Philippines, Vietnam), indicative of pending orders and potential new market entries.
- →Transition to Mainboard and capital investments (e.g., new corporate office, API intermediate plant search) demonstrate readiness to handle increased order volumes.
- →Management emphasizes a robust pipeline for the next 3-4 years and consistent growth of 23%-30% annually across segments, signifying a positive outlook on order inflow.
Key Metrics
Frequently Asked Questions
What were Beta Drugs Ltd Q4 FY25 results?
Company aims to grow at a rate between 23%-30% annually across key segments. - Domestic own branded business expected to continue 25%+ growth. - CDMO business expected to grow 5%-10% annually. - Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through. - Dermatology (Derma) segment expected to grow from Rs. Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year. - The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years. - EBITDA margins are expected to be stable around 23% to 25% consolidated. - The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs.
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place.
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.